Sinno Biopharmaceuticals Limited has published its annual report for the year ended 31 December 2023. The report shows that the company has made significant progress in areas such as oncology, liver disease, respiratory diseases and orthopedic/pain management, transforming from generic pharmaceutical transformation to innovative drug development. Sinno Biopharmaceutics' main innovations include alotinic capsules and pasurilone anti-injection solution for cancer, as well as Budinid inhalation suspension for respiratory diseases, etc. In fiscal 2023, the company achieved a revenue of RMB261 billion and a net profit of RMB23.3 billion attributable to the owners of the company. Cinno Biopharmaceuticals has 43 tumor candidate drugs in clinical development and is expected to receive new drug approval in the coming years. The company actively cooperates internationally with the aim...Show More

Sinno Biopharmaceuticals Limited has published its annual report for the year ended 31 December 2023. The report shows that the company has made significant progress in areas such as oncology, liver disease, respiratory diseases and orthopedic/pain management, transforming from generic pharmaceutical transformation to innovative drug development. Sinno Biopharmaceutics' main innovations include alotinic capsules and pasurilone anti-injection solution for cancer, as well as Budinid inhalation suspension for respiratory diseases, etc. In fiscal 2023, the company achieved a revenue of RMB261 billion and a net profit of RMB23.3 billion attributable to the owners of the company. Cinno Biopharmaceuticals has 43 tumor candidate drugs in clinical development and is expected to receive new drug approval in the coming years. The company actively cooperates internationally with the aim of capturing the international market through innovative products and achieving significant sales growth through positive management measures, despite the price pressure of centralized procurement. In addition, Sino-Biopharmaceuticals in the respiratory field includes 8 innovative candidate drugs in clinical and above development stages, which are expected to receive new product approval in the next three years (2024-2026). In 2023, the company was recognized in several rankings such as “Top 50 Innovative Pharmaceutical Companies in China” and “Top 100 Competitive List of Chinese Pharmaceuticals”.